Snapshot from Aug 23, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / BlossomHill Therapeutics $150M IPO Pricing
Business initial public offering

BlossomHill Therapeutics $150M IPO Pricing

Analysis based on 8 articles · First reported Aug 07, 2026 · Last updated Aug 07, 2026

Sentiment
60
Attention
4
Articles
8
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The successful IPO provides BlossomHill Therapeutics with approximately $150 million in capital to advance its oncology pipeline, potentially boosting investor confidence in the biotech sector. The offering's upsizing and pricing at $16 per share indicate strong demand, which may positively influence sentiment for similar clinical-stage biopharmaceutical companies.

Biopharmaceuticals Oncology
Event Summary

BlossomHill Therapeutics, a clinical-stage biopharmaceutical company focused on developing small molecule cancer treatments, priced its upsized initial public offering of 9,375,000 shares of common stock at $16.00 per share, raising gross proceeds of $150.0 million. The shares are expected to begin trading on the Nasdaq Global Select Market on August 7, 2026, under the ticker symbol 'BLSM', with the offering expected to close on August 10, 2026. The company granted underwriters a 30-day option to purchase up to an additional 1,406,250 shares. JPMorgan Chase, Leerink Partners, and Guggenheim Partners acted as lead book-running managers, with LifeSci Capital and H.C. Wainwright & Co. as joint book-running managers. The registration statements were declared effective by the United States — United States Securities and Exchange Commission on August 6, 2026. BlossomHill Therapeutics is led by J. Jean Cui, a veteran in oncology drug development, and its lead programs include BH-30643 for EGFR-mutant non-small cell lung cancer and BH-30236 for acute myeloid leukemia.

Key Actions
100 BlossomHill Therapeutics priced IPO
80 United States — United States Securities and Exchange Commission declared registration effective BlossomHill Therapeutics
60 BlossomHill Therapeutics granted underwriters option
Entities Involved
priv
BlossomHill Therapeutics
BlossomHill Therapeutics is the issuer of the IPO, raising $150 million to fund its clinical programs. The successful offering enhances its financial position and validates its pipeline, positively impacting its market sentiment.
Importance 100.0 Sentiment 70.0
stock
JPMorgan Chase
JPMorgan Chase acted as a lead book-running manager for the IPO, earning underwriting fees and strengthening its position in biotech capital markets. The successful offering reflects positively on its investment banking franchise.
Importance 80.0 Sentiment 60.0
priv
Leerink Partners
Leerink Partners served as a lead book-running manager, generating underwriting revenue and reinforcing its expertise in healthcare IPOs. The deal enhances its reputation in the sector.
Importance 80.0 Sentiment 60.0
priv
Guggenheim Partners
Guggenheim Partners acted as a lead book-running manager, earning fees and demonstrating its capability in executing biotech IPOs. The successful offering supports its investment banking business.
Importance 80.0 Sentiment 60.0
per
J. Jean Cui
J. Jean Cui is the founder and CEO of BlossomHill Therapeutics, and her leadership and track record were highlighted in the IPO. The successful offering enhances her reputation and the company's credibility.
Importance 70.0 Sentiment 65.0
priv
LifeSci Capital
LifeSci Capital participated as a joint book-running manager, gaining underwriting fees and exposure in the biotech IPO market. The deal contributes to its deal flow and industry standing.
Importance 60.0 Sentiment 55.0
priv
H.C. Wainwright & Co.
H.C. Wainwright & Co. served as a joint book-running manager, earning fees and reinforcing its presence in healthcare capital markets. The offering adds to its track record.
Importance 60.0 Sentiment 55.0
govactor
United States — United States Securities and Exchange Commission
The SEC declared the registration statements effective, enabling the IPO to proceed. This regulatory action is routine but essential for the offering's completion.
Importance 50.0 Sentiment 50.0
exch
Nasdaq
Nasdaq will list BlossomHill Therapeutics' shares under the ticker 'BLSM', adding a new biotech company to its exchange. This listing is a routine but positive addition to its roster.
Importance 40.0 Sentiment 50.0
Relationships
JPMorgan Chase related ↔ Guggenheim Partners
JPMorgan Chase related ↔ United States — United States Securities and Exchange Commission
JPMorgan Chase related ↔ Nasdaq
Leerink Partners related ↔ Guggenheim Partners
Leerink Partners related ↔ United States — United States Securities and Exchange Commission
Leerink Partners related ↔ Nasdaq
Guggenheim Partners related ↔ United States — United States Securities and Exchange Commission
Guggenheim Partners related ↔ Nasdaq
LifeSci Capital related ↔ United States — United States Securities and Exchange Commission
United States — United States Securities and Exchange Commission related ↔ Nasdaq
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.